Treatment of hemophilia A and B and von willebrand disease

Berntorp E, Astermark J, Baghaei F, Bergqvist D, Holmstrom M, Ljung R, Ljungberg B, Nilstun T, Norlund A, Palmblad J, Petrini P, Stigendal L, Sawe J, Lindblom J, Syversson A
Record ID 32011001014
Authors' objectives:

This review aims to assess – from medical, economic, and ethical perspectives – different dosing strategies for replacement therapy using coagulation factor concentrates to treat patients with hemophilia A and B and von Willebrand disease.
The systematic literature review does not cover the safety aspects related to transmission of infections, or the risks for developing inhibitors (neutralising antibodies). The methods currently used for virus inactivation and virus reduction in producing plasma-based factor concentrates have been approved by European and U.S. drug authorities, and the products
are considered to have a wide margin of safety. The transition to products manufactured by recombinant DNA methods has favourably altered the risks of blood contamination. An international debate is under way concerning the risks of inhibitor development, but evidence supporting the various opinions is deficient. Even a minor difference could have considerable medical and economic consequences.

Project Status: Completed
Year Published: 2011
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Sweden
MeSH Terms
  • Hemophilia A
  • von Willebrand Diseases
Organisation Name: Swedish Agency for Health Technology Assessment and Assessment of Social Services
Contact Address: P.O. Box 3657, SE-103 59 Stockholm, Sweden. Tel: +46 8 4123200, Fax: +46 8 4113260
Contact Name:
Contact Email:
Copyright: The Swedish Council on Health Technology Assessment (SBU)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.